Bradley Foster & Sargent Inc. CT Sells 1,850 Shares of CVS Health Co. (NYSE:CVS)

Bradley Foster & Sargent Inc. CT decreased its holdings in CVS Health Co. (NYSE:CVS) by 7.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,376 shares of the pharmacy operator’s stock after selling 1,850 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in CVS Health were worth $1,004,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. MidAtlantic Capital Management Inc. bought a new stake in CVS Health in the 3rd quarter worth about $25,000. Ridgewood Investments LLC boosted its holdings in shares of CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock valued at $28,000 after acquiring an additional 450 shares during the last quarter. Stonebridge Financial Group LLC bought a new stake in shares of CVS Health in the fourth quarter worth approximately $28,000. Legacy Investment Solutions LLC purchased a new position in shares of CVS Health during the third quarter valued at approximately $31,000. Finally, Reston Wealth Management LLC bought a new position in CVS Health during the third quarter valued at approximately $32,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Activity

In other news, Director Michael F. Mahoney acquired 30,000 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.24% of the company’s stock.

CVS Health Trading Down 2.6 %

Shares of CVS opened at $63.42 on Friday. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company’s fifty day moving average is $52.39 and its 200 day moving average is $56.22. The stock has a market capitalization of $79.95 billion, a PE ratio of 17.33, a P/E/G ratio of 0.98 and a beta of 0.61.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. Sell-side analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.19%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is 72.68%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. UBS Group decreased their target price on shares of CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday, February 11th. Leerink Partners upgraded CVS Health from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $55.00 to $75.00 in a research report on Thursday, February 13th. Edward Jones raised CVS Health from a “hold” rating to a “buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a research report on Tuesday, December 3rd. Finally, Barclays raised their price objective on shares of CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $70.00.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.